https://arolstar52-zhtest.hf.space/index.php?action=history&feed=atom&title=UBCS039
UBCS039 - 版本历史
2026-07-18T19:59:16Z
本wiki上该页面的版本历史
MediaWiki 1.43.9
https://arolstar52-zhtest.hf.space/index.php?title=UBCS039&diff=4766115&oldid=prev
imported>Yyfroy：正式称呼
2026-02-09T11:27:48Z
<p>正式称呼</p>
<p><b>新页面</b></p><div>{{Infobox drug<br />
| drug_name = <br />
| image = UBCS039_structure.png<br />
| width = <br />
| caption = <br />
<br />
<!-- Clinical data --><br />
| pronounce = <br />
| tradename = <br />
| Drugs.com = <br />
| MedlinePlus = <br />
| licence_CA = <br />
| licence_EU = <br />
| DailyMedID = <br />
| licence_US = <br />
| pregnancy_AU = <br />
| pregnancy_category = <br />
| dependency_liability = <br />
| addiction_liability = <br />
| routes_of_administration = <br />
| class = [[Sirtuin 6|Sirtuin-6]] (SIRT6) activator<br />
| ATC_prefix = <br />
| ATC_suffix = <br />
<br />
<!-- Legal status --><br />
| legal_status = <br />
<br />
<!-- Pharmacokinetic data --><br />
| bioavailability = <br />
| protein_bound = <br />
| metabolism = <br />
| metabolites = <br />
| onset = <br />
| elimination_half-life = <br />
| duration_of_action = <br />
| excretion = <br />
<br />
<!-- Identifiers --><br />
| CAS_number = 358721-70-7<br />
| PubChem = 2803797<br />
| IUPHAR_ligand = <br />
| DrugBank = <br />
| ChemSpiderID = <br />
| UNII = <br />
| KEGG = <br />
| ChEBI = <br />
| ChEMBL = <br />
<br />
<!-- Chemical data --><br />
| IUPAC_name = 4-pyridin-3-yl-4,5-dihydropyrrolo[1,2-a]quinoxaline<br />
| C=16 | H=13 | N=3<br />
| SMILES = C1=CC=C2C(=C1)NC(C3=CC=CN32)C4=CN=CC=C4<br />
| StdInChI = 1S/C16H13N3/c1-2-7-14-13(6-1)18-16(12-5-3-9-17-11-12)15-8-4-10-19(14)15/h1-11,16,18H<br />
| StdInChIKey = BSOBGTYXYGHUTD-UHFFFAOYSA-N<br />
}}<br />
<br />
'''{{PAGENAME}}'''是一种[[氮化合物|含氮]][[杂环化合物]]，分子式[[C16H13N3|C<sub>16</sub>H<sub>13</sub>N<sub>3</sub>]]，可作为[[二磷酸腺苷核糖基化]]酶[[Sirtuin 6|Sirtuin-6]]（SIRT6）的激活剂，用于[[抗炎]]药。<ref>{{cite journal | vauthors = Wang D, Zhou Y, Yang N, Liu J, Lu L, Gao Z | title = SIRT6 mitigates acute kidney injury by enhancing lipid metabolism and reducing tubular epithelial cell apoptosis via suppression of the ACMSD signaling pathway | journal = Cellular Signalling | volume = 131 | article-number = 111757 | date = July 2025 | pmid = 40120964 | doi = 10.1016/j.cellsig.2025.111757 }}</ref><ref>{{cite journal | vauthors = Sinha R, Singh P, Zeng H, Kumar A, Antony VB | title = Cadmium exposure triggers vimentin phosphorylation via SIRT6-regulated AKT/PI3K signaling pathway in COPD | journal = European Journal of Cell Biology | volume = 104 | issue = 3 | article-number = 151503 | date = September 2025 | pmid = 40609497 | doi = 10.1016/j.ejcb.2025.151503 }}</ref><br />
<br />
==参考文献==<br />
{{reflist}}<br />
<br />
[[Category:喹喔啉]]<br />
[[Category:3-吡啶基化合物]]</div>
imported>Yyfroy